Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
AssigneeInstil Bio (UK) Limited
InventorsRyan Guest, Joanne McCaffrey
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and/or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.
Claims14
A method of identifying potent T-cells in a population of TILs, comprising:
- in an isolated and ex vivo expanded population of TILs from a subject's cancer tissue, identifying the presence of T-cells expressing a combination of markers, the combination comprising each of:
- CD107a;
- CD137;
- TNF-α;
- and,
- IFN-γ;
- wherein, a T-cell is determined to be potent by the presence of the combination of markers.
A method of identifying potent T-cells in a population of TILs, comprising:
- in an isolated and ex vivo expanded population of TILs from a subject's cancer tissue, identifying CD2+ T-cells expressing a combination of markers, the combination comprising each of:
- a T-cell expressing CD107a;
- a T-cell expressing CD 137;
- a T-cell expressing TNF-α;
- and,
- a T-cell expressing IFN-γ;
- wherein, a T-cell is determined to be potent by the presence of the combination of markers.
A method of determining potency of a population of TILs, comprising:
- in an isolated and ex vivo expanded population of TILs from a subject's cancer tissue, quantifying T-cells expressing a combination of markers, the combination comprising each of:
- a T-cell expressing CD 107a;
- a T-cell expressing CD 137;
- a T-cell expressing TNF-α;
- and,
- a T-cell expressing IFN-γ;
- wherein, a T-cell is determined to be potent by the presence of the combination of markers;
- quantifying the total number of T-cells in the expanded population of TILs;
- and,
- determining the percent potency of the expanded population of TILs by the ratio of T-cells expressing the combination of markers to the total number of T-cells in the expanded population of TILs.
A method for treating cancer in a subject comprising identifying potent T-cells in a population of TILs, comprising:
- in an isolated and ex vivo expanded population of TILs from a subject's cancer tissue, identifying the presence of T-cells expressing a combination of markers, the combination comprising each of:
- CD107a;
- CD137;
- TNF-α;
- and,
- IFN-γ;
- wherein, a T-cell is determined to be potent by the presence of the combination of markers,
- and administering to the subject the identified potent T-cells.
Dependencies are inferred from the claim text.